A man shot by police after pointing a high-powered pellet gun at police officers in a Target parking lot in Woodbury was ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...

Roche (RHHBY) reportedly sees three obesity/diabetes drug candidates acquired through its takeover of Carmot having the ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the ...

Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...